Roanna Ruiz
Stock Analyst at Leerink Partners
(0.76)
# 3,781
Out of 4,854 analysts
63
Total ratings
30.77%
Success rate
-18.78%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $3.97 | +76.32% | 1 | Apr 28, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $5 → $6 | $4.58 | +31.00% | 5 | Mar 7, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $13.98 | +28.76% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $0.77 | +30.43% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $5.46 | +266.64% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $14.49 | +86.34% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $3.56 | +265.17% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $3.68 | +280.43% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $325.44 | +1.40% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $32.28 | +79.68% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $69.60 | -64.08% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $7.48 | +555.08% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $4.20 | +209.52% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.18 | +88.98% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $20.17 | -5.80% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $81.55 | +47.15% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $7.16 | +598.32% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $12.72 | +214.47% | 6 | Oct 19, 2022 |
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $3.97
Upside: +76.32%
Xeris Biopharma Holdings
Mar 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $4.58
Upside: +31.00%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $13.98
Upside: +28.76%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.77
Upside: +30.43%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $5.46
Upside: +266.64%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $14.49
Upside: +86.34%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $3.56
Upside: +265.17%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $3.68
Upside: +280.43%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $325.44
Upside: +1.40%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $32.28
Upside: +79.68%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $69.60
Upside: -64.08%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $7.48
Upside: +555.08%
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $4.20
Upside: +209.52%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.18
Upside: +88.98%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $20.17
Upside: -5.80%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $81.55
Upside: +47.15%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $7.16
Upside: +598.32%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $12.72
Upside: +214.47%